Glumet XR Adverse Reactions

In post-marketing data and in controlled clinical studies, adverse event reporting in patients treated with Glumet XR was similar in nature and severity to that reported in patients treated with metformin immediate-release.
The following undesirable effects may occur with metformin. Frequencies are defined as follows: Very common >1/10; common ≥1/100, <1/10; uncommon ≥1/1000, <1/100; rare ≥1/10,000, <1/1000; very rare <1/10,000; not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Metabolism and Nutrition Disorders: Very Rare: Decrease of vitamin B12 absorption with decrease of serum levels during long-term use of metformin. Consideration of such an aetiology is recommended if a patient presents with megaloblastic anaemia.
Nervous System Disorders: Common: Taste disturbance.
Gastrointestinal Disorders: Very Common: Gastrointestinal disorders eg, nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. A slow increase of the dose may also improve gastrointestinal tolerability.
Hepatobiliary Disorders: Not Known: Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.
Skin and Subcutaneous Tissue Disorders: Very Rare: Skin reactions eg, erythema, pruritus, urticaria.